2021
Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy
Wells CR, Cao Y, Durham DP, Byrareddy SN, Ansari AA, Ruddle NH, Townsend JP, Galvani AP, Perelson AS. Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy. PLOS Computational Biology 2021, 17: e1009031. PMID: 34106916, PMCID: PMC8189501, DOI: 10.1371/journal.pcbi.1009031.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyViral loadPost-treatment controlAnti-α4β7 antibodyViral remissionAntibody treatmentViral controlCombinations of cARTImmune effector cell responsesPost-treatment viral controlSIV RNA copies/Depletion of CD8Ongoing immune responseEarly SIV infectionRNA copies/Stable viral loadEffector cell responsesViral load dataDifferent viral loadsAbsence of treatmentSubset of animalsNonhuman primate experimentsDifferent primary mechanismsLongitudinal viral load dataCART cessation
2018
Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study
Marshall BDL, Goedel WC, King MRF, Singleton A, Durham DP, Chan PA, Townsend JP, Galvani AP. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. The Lancet HIV 2018, 5: e498-e505. PMID: 29908917, PMCID: PMC6138558, DOI: 10.1016/s2352-3018(18)30097-3.Peer-Reviewed Original ResearchConceptsNew HIV infectionsInjectable PrEPPre-exposure prophylaxisOral PrEPHIV infectionHIV transmissionInjectable pre-exposure prophylaxisOral pre-exposure prophylaxisAbsence of PrEPDaily oral PrEPTime-varying efficacyPhase 3 trialRetention of patientsNational InstituteDiscontinuation ratesSafety trialMacaque modelHIV preventionCumulative numberClinical carePharmacokinetic dataCoverage levelsPotential effectivenessPopulation-level impactInfection